Krystal Biotech, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.krystalbio.com

Earnings Score
Moat Score

Market Cap $3.91B
PE 44
Debt -
Cash $344.87M
EV -
FCF $119.18M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$89.16M
EBIT	$95.36M
ROE	9%
ROA	9%
FCF	$119.18M
Equity	$946.38M
Growth Stability	1
PE	43.8
PEG	21.87
PB	4.13
P/FCF	32.77
P/S	13.44
Price/Cash	0.09
Net Margins	31%
Op. Margins	33%
Earnings CAGR	0%
Sales Growth YoY	116%
Sales Growth QoQ	9%
Sales CAGR	1%
Equity CAGR	75%
Earnings Stability	-0.16

Earnings Growth YoY	423%
Earnings Growth QoQ	67%
Earnings CAGR 5Y	2%
Sales CAGR 5Y	7%
Equity CAGR 5Y	31%
Earnings CAGR 3Y	162%
Sales CAGR 3Y	162%
Equity CAGR 3Y	27%
Market Cap	$3.91B
Revenue	$290.52M
Assets	$1.06B
Cash	$344.87M
Shares Outstanding	28.58M
Earnings Score	6%
Moat Score	91%
Working Capital	640.05M
Current Ratio	7.28
Shares Growth 3y	6%
Equity Growth QoQ	7%
Equity Growth YoY	22%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.

SEC Filings

Direct access to Krystal Biotech, Inc. (KRYS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Krystal Biotech, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Krystal Biotech, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%

Stability -16%

loading chart...

Krystal Biotech, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Krystal Biotech, Inc..

Years

Calculation mode

= $1.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$119M	$119M	$119M	$119M	$119M	$119M	$119M	$119M	$119M	$119M	$119M	$1.2B
DCF		$108M	$98M	$90M	$81M	$74M	$67M	$61M	$56M	$51M	$46M	$459M
Value	$1.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-	-	-	-	-	22%	31%	31%
ROA	-	-10%	-10%	-11%	-11%	-11%	-25%	2%	9%	9%
ROE	-	-16%	-10%	-9%	-11%	-12%	-27%	1%	9%	9%

Good Net Margins (30.69%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	3.96	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-	473%	7%
Earnings YoY growth	-	589%	37%	75%	69%	116%	101%	-108%	716%	2%
Equity YoY growth	-	17K%	129%	79%	44%	103%	-12%	49%	22%	31%
FCF YoY growth	-	209%	185%	115%	63%	184%	32%	-34%	-218%	-